Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule | WAPE

Newsbenzinga

Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Sep 3, 2026, 13:52 ET · Published

Article summary

Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.

An excerpt from the original article.

Related companies

CLYMCLYMView stock

Comments —

Comment

Loading comments…